[CAR-T: an effective option in primary refractory patients].
1/5 보강
Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), setting as the new standard of care.
APA
Tisi MC, Wieczorek M, Riva M (2026). [CAR-T: an effective option in primary refractory patients].. Recenti progressi in medicina, 117(2), e47-e51. https://doi.org/10.1701/4649.46637
MLA
Tisi MC, et al.. "[CAR-T: an effective option in primary refractory patients].." Recenti progressi in medicina, vol. 117, no. 2, 2026, pp. e47-e51.
PMID
41716111 ↗
Abstract 한글 요약
Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved the prognosis of patients with diffuse large B-cell lymphoma (DLBCL), setting as the new standard of care. Below, we describe the case history of a 69-year-old female patient diagnosed with DLBCL, treated in 2024 with axi-cel for refractory disease to first-line with R-CHOP, after bridging therapy with PolaBR and associated radiotherapy. 18F-FDG-PET scan performed one month after CAR-T therapy showed complete remission of the lymphoma, and the patient is still in remission, at more than one year after the infusion. Patient treatment after infusion required the management of a CRS and ICANS requiring tocilizumab for CRS and subsequently dexamethasone for the ICANS, with rapid resolution of symptoms. This experience confirms the potential efficacy of axi-cel in a very extensive, symptomatic, and chemorefractory disease, and is very informative due to the specific immuno-effector T cell toxicities that occurred, both for the importance of their recognition and for the importance of their early treatment. These factors now ensure that safety considerations are no longer a barrier to offering the most effective treatment to this group of patients.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Female
- Aged
- Lymphoma
- Large B-Cell
- Diffuse
- Immunotherapy
- Adoptive
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies
- Monoclonal
- Humanized
- Dexamethasone
- Cyclophosphamide
- Positron-Emission Tomography
- Receptors
- Chimeric Antigen
- Treatment Outcome
- Vincristine
- Doxorubicin
- Prednisone
- Rituximab
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.